docetaxel anhydrous has been researched along with abiraterone in 189 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 942 | 97 | 854 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | abiraterone (IC50) |
|---|---|---|---|
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | 0.2557 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.0643 | |
| Steroid 21-hydroxylase | Homo sapiens (human) | 0.1642 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Rattus norvegicus (Norway rat) | 0.0674 | |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 1.5714 | |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 1.722 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 141 (74.60) | 24.3611 |
| 2020's | 48 (25.40) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Anand, A; Bubley, GJ; Danila, DC; de Bono, JS; Denmeade, SR; Fleisher, M; Haqq, C; Kheoh, T; Koscuiszka, M; Larson, SM; Molina, A; Morris, MJ; Ryan, CJ; Scher, HI; Schwartz, LH; Smith, MR; Taplin, ME | 1 |
| Attard, G; Danila, DC; de Bono, JS; Dearnaley, D; Fong, PC; Hunt, J; Kheoh, T; Lee, G; Messiou, C; Molife, LR; Molina, A; Olmos, D; Oommen, NB; Parker, C; Reid, AH; Ryan, CJ; Scher, HI; Small, E; Swennenhuis, JF; Terstappen, LW | 1 |
| Pal, SK; Sartor, O | 3 |
| Goetz, D | 1 |
| Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R | 1 |
| Miller, K | 1 |
| Petrylak, DP | 1 |
| Gelpi, F; Gomella, LG; Kelly, WK | 1 |
| Higano, CS | 1 |
| de Bono, JS; Massard, C; Michels, RM; Sartor, O | 1 |
| Börgermann, C; Molitor, B | 1 |
| Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M | 1 |
| Herchenhorn, D; Maluf, FC; Smaletz, O | 1 |
| Kim, W; Ryan, CJ | 1 |
| Attard, G; Baikady, B; Bianchini, D; de Bono, J; Hunt, J; Maier, G; Mezynski, J; Mulick Cassidy, A; Olmos, D; Pezaro, C; Reid, AHM; Sandhu, S; Sarvadikar, A; Sheridan, E; Thompson, E; Zivi, A | 1 |
| Gottfried, M; Keizman, D; Maimon, N | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Aapro, MS | 1 |
| Adler, AI; Dyer, M; George, E; Rinaldi, F | 1 |
| Lewis, B; Pal, SK; Sartor, O | 1 |
| Petrányi, Á | 1 |
| Birtle, A | 1 |
| Albiges, L; Attard, G; Bianchini, D; De Bono, JS; Fizazi, K; Ileana, E; Loriot, Y; Massard, C; Patrikidou, A; Pezaro, C; Sandhu, S | 1 |
| Hotte, SJ; Loblaw, DA; Walker-Dilks, C; Winquist, E | 1 |
| Aparicio, AM; Goldkorn, A; Quinn, DI | 1 |
| Boegemann, M; Cronauer, MV; Hajili, T; Herrmann, E; Jentzmik, F; Krabbe, LM; Ohlmann, CH; Schnoeller, TJ; Schrader, AJ; Schrader, M; Stoeckle, M | 1 |
| Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Mukherji, D; Omlin, A; Parker, C; Pezaro, CJ; Sandhu, S; Van As, N; Zaidi, S | 1 |
| Gallego, IG; Garcia-Carbonero, R; Giménez, EV; Giuliani, R; Gravanis, I; Hemmings, RJ; Jiménez, JC; Lopez, AS; O'Connor, D; Pignatti, F; Salmonson, T | 1 |
| Attard, G; Bianchini, D; Chowdhury, S; de Bono, JS; Ferraldeschi, R; Lorente, D; Omlin, A; Pezaro, C; Rodriguez-Vida, A; Zivi, A | 1 |
| Fizazi, K; Loriot, Y | 1 |
| de Morrée, ES; de Wit, R; Mathijssen, RH; Moll, JM; Teubel, W; van Royen, ME; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Basset, V; Crouzet, S; Flamand, V; Ploussard, G | 1 |
| D'Amico, AV | 1 |
| Badrising, S; Bergman, AM; Coenen, JL; de Jong, IJ; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Tinteren, H | 1 |
| Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Omlin, AG; Parker, C; Pezaro, CJ | 1 |
| Böker, A; Geith, A; Gschwend, JE; Kuczyk, M; Merseburger, AS; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; von Klot, C | 1 |
| Bahl, A | 1 |
| Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC | 1 |
| Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Ferraldeschi, R; Grist, E; Lorente, D; Mateo, J; Ravi, P; Sideris, S; Smith, A; Wong, S; Zafeiriou, Z | 1 |
| Fizazi, K; Loriot, Y; Massard, C | 1 |
| Albers, P; Eichenauer, R; Geiges, G; Grimm, MO; König, F; Mickisch, G; Miller, K; Pfister, D; Schwentner, C; Suttmann, H; Zastrow, S | 1 |
| Al Nakouzi, N; Albigès, L; Beuzeboc, P; de La Motte Rouge, T; Fizazi, K; Gajda, D; Gleave, M; Gross-Goupil, M; Guillot, A; Le Moulec, S; Loriot, Y; Massard, C; Wang, C | 1 |
| Tombal, B | 1 |
| Bellmunt, J; de Bono, JS; Efstathiou, E; Kheoh, T; Li, J; Loriot, Y; Molina, A; Montgomery, B; Ryan, CJ; Scher, HI; Tran, N | 1 |
| Antonarakis, ES; Luber, B; Nadal, R; Schweizer, MT; Suzman, DL | 1 |
| Byun, SS; Hong, SJ; Kheoh, T; Kim, CS; Kwak, C; Lee, HM; Ou, YC; Rhim, HY; Wan, Y; Wu, HC; Wu, TT; Yeh, H; Yu, MK | 1 |
| Boegemann, M; Brasso, K; de Bono, J; Lorente, D; Merseburger, AS; Retz, M; Schmid, SC; Schrader, AJ; Thomsen, FB; von Klot, CA | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Azad, AA; Chi, KN; Eigl, BJ; Heng, DY; Joshua, AM; Kollmannsberger, C; Leibowitz-Amit, R; Lester, R; Murray, RN; Wells, JC | 1 |
| Griffin, TW; Nandy, P; Poggesi, I; Ryan, CJ; Saad, F; Smith, MR; Stuyckens, K; Vermeulen, A; Xu, XS; Yu, MK | 1 |
| Alibhai, SM; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Sridhar, SS; Tannock, IF; Templeton, AJ | 1 |
| Akaza, H; Imanaka, K; Nakatani, T; Nishiyama, T; Ozono, S; Satoh, T; Tanabe, K; Terai, A; Uemura, H; Yokomizo, A | 1 |
| Saad, F | 1 |
| Agarwal, N; Antonarakis, ES; Azad, A; Batten, JA; Cheng, HH; Chi, KN; Galsky, MD; Gulati, R; Heath, EI; Leiter, A; Montgomery, RB; Nadal, R; Pal, SK; Rehman, HT; Twardowski, P; Vaishampayan, UN; Yu, EY | 1 |
| Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T | 1 |
| Anderson, SA; Azad, AA; Bazov, J; Bell, RH; Chi, KN; Collins, CC; Gleave, ME; Haegert, A; Le Bihan, S; McConeghy, B; Paris, P; Shukin, R; Small, EJ; Thomas, G; Volik, SV; Wang, Y; Wyatt, AW; Youngren, J | 1 |
| Ndibe, C; Sonpavde, G; Wang, CG | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Eisenberger, MA; Lu, C; Luo, J; Nakazawa, M; Paller, CJ | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Nadal, R; Nakazawa, M; Paller, CJ; Wang, H | 1 |
| Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
| Bergman, AM; Bos, MM; Chitu, D; de Morrée, ES; de Wit, R; Goey, SH; Hamberg, P; Mathijssen, RH; Nieuweboer, AJ; van der Meer, N; van Soest, RJ | 1 |
| Antonarakis, ES; Bassi, S; Maughan, BL; Nadal, R; Schweizer, MT; Suzman, DL; Xhou, XC | 1 |
| Bria, E; Caffo, O; Galligioni, E; Maines, F; Tortora, G; Trentin, C; Veccia, A | 1 |
| Audenet, F; Basset, V; Branchereau, J; de La Taille, A; Flamand, V; Lebdai, S; Lebret, T; Murez, T; Neuzillet, Y; Ploussard, G | 1 |
| Ohlmann, CH | 1 |
| Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S; Warmerdam, F | 1 |
| Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fratino, L; Gasparro, D; Giordano, M; Lo Re, G; Lolli, C; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Veccia, A; Verderame, F; Zagonel, V | 1 |
| Antonarakis, ES; Maughan, BL | 1 |
| Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Davies, RS; Lester, JF; Smith, C | 1 |
| Adamo, V; Barni, S; Boccardo, F; Bruno, M; Caffo, O; Caserta, C; Chiuri, VE; De Giorgi, U; De Vincenzo, F; De Vivo, R; Derosa, L; Dinota, A; Facchini, G; Fratino, L; Grassi, P; Messina, C; Mosca, A; Porcu, L; Procopio, G; Ricotta, R; Santini, D; Scavelli, C; Surace, G; Susi, M; Tartarone, A; Verzoni, E; Zaniboni, A | 1 |
| Arslan, C | 1 |
| Aghai, A; Böttcher, R; Burger, H; de Morrée, ES; de Ridder, CM; de Wit, R; Gibson, AA; Mathijssen, RH; Sparreboom, A; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Balea-Filgueiras, J; Martín-Herranz, I; Ramudo-Cela, L; Vizoso-Hermida, JR | 1 |
| Cookson, MS; Ritch, CR | 1 |
| Aitoku, Y; Basurto, E; Concialdi, K; DiBonaventura, M; Kimura, G; Ledesma, DA; Matsubara, N; McKinnon, I; Mohamed, AF; Narimatsu, A; Uemura, H; Wang, E; Yamaguchi, A | 1 |
| Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A | 1 |
| Armstrong, A; Balk, M; Brown, B; Bui, C; Chambers, J; Deangelis, J; Fitch, K; Flanders, S; Sawhney, TG | 1 |
| Berdah, JF; Culine, S; Massard, C; Pasquier, D; Penel, N; Turpin, A | 1 |
| Gallagher, M; Reinhart, M; Sartor, O; Summers, N; Vanderpuye-Orgle, J | 1 |
| Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N | 1 |
| Cheng, WY; Dhawan, R; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Sung, J; Vekeman, F | 1 |
| Boccardo, F; Messina, C; Messina, M | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Harada, KI; Hinata, N; Nakano, Y; Terakawa, T | 1 |
| Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A | 1 |
| James, ND; Spears, MR; Sydes, MR | 1 |
| Enokida, H; Inoue, S; Ishibashi, K; Izumi, K; Kamiyama, M; Kawai, N; Mizokami, A; Namiki, M; Shima, T; Takahara, S; Tanaka, N; Yoshio, Y | 1 |
| Lundholm, M; Nilsson, RJA; Schröder, M; Thellenberg-Karlsson, C; Tjon-Kon-Fat, LA; Widmark, A; Wikström, P; Wurdinger, T | 1 |
| Aggarwal, R | 1 |
| Burgio, SL; Caroli, P; Casadio, V; Conteduca, V; De Giorgi, U; Gurioli, G; Lolli, C; Matteucci, F; Menna, C; Paganelli, G; Salvi, S; Scarpi, E; Schepisi, G; Testoni, S | 1 |
| Bansal, S; Emmenegger, U; Kulkarni, GS; Nam, RK; Saskin, R; Satkunasivam, R; Wallis, CJD | 1 |
| Antonarakis, ES; Armstrong, AJ; McNamara, M; Sweeney, C | 1 |
| Atkins, KM; Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, M; Renshaw, AA; Small, EJ; Wu, J | 1 |
| Cai, W; Chi, C; Dong, B; Fan, L; Pan, J; Qian, H; Shangguan, X; Shao, X; Wang, R; Wang, Y; Xu, F; Xue, W; Zhang, Y; Zhou, L; Zhu, Y | 1 |
| Heidenreich, A; Nilsson, S; Parker, C; Shore, N | 1 |
| Baser, O; Huang, A; Miao, R; Sonpavde, G; Wang, L | 1 |
| Elkon, JM; Lin, J; Millado, KF; Millett, RL | 1 |
| Gourdin, T | 2 |
| Bangs, R; Basch, E; Celano, P; Hotte, SJ; Loblaw, A; Milowsky, MI; Morris, MJ; Rathkopf, D; Rumble, RB | 1 |
| Alexander, DD; Deuson, R; Fryzek, JP; Reichert, H; Summers, N; Townes, L; Vanderpuye-Orgle, J | 1 |
| Efstathiou, E | 1 |
| Aguiar, P; Haaland, B; Lopes, G; Tan, PS | 1 |
| Ali, R; Chambers, C; Ghosh, S; North, S; Sawyer, M; Shivji, A | 1 |
| Fizazi, K; Hamilou, Z; Saad, F | 1 |
| Akaza, H; Buchan, NC; Chiong, E; Chung, BH; Davis, ID; Kanesvaran, R; Khochikar, M; Le Chuyen, V; Letran, J; Lojanapiwat, B; Murphy, DG; Ng, CF; Ong, T; Pu, YS; Saad, M; Schubach, K; Türkeri, L; Umbas, R; Williams, S; Ye, DW | 1 |
| Pachynski, RK; Xu, L | 1 |
| Baldauf, S; Bartsch, G; Borgmann, H; Brandt, MP; Dotzauer, R; Frees, S; Haferkamp, A; Jäger, W; Neisius, A; Schneider, M; Thomas, C; Tsaur, I | 1 |
| Cheng, WY; Drea, E; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Szatrowski, TP; Vekeman, F | 1 |
| Basso, U; Caffo, O; Campadelli, E; Conteduca, V; De Giorgi, U; Facchini, G; Fratino, L; Gasparro, D; Kinspergher, S; Maines, F; Massari, F; Messina, C; Mosillo, C; Procopio, G; Rossetti, S; Sabbatini, R; Sava, T; Scagliarini, S; Sirotova, S; Veccia, A; Verzoni, E | 1 |
| Bolognini, C; Gassian, N; Klajer, E; Loriot, Y; Meynard, G; Thiery-Vuillemin, A | 1 |
| Belov, AV; Faustova, MR; Mollaev, MD; Nikolskaya, ED; Severin, ES; Sokol, MB; Tereshchenko, OG; Yabbarov, NG; Zabolotsky, AI; Zenin, VA; Zhunina, OA | 1 |
| Chen, J; Gao, AC; Liao, B; Liu, J; Liu, Z; Shen, P; Shu, K; Sun, G; Yang, Y; Zeng, H; Zhang, X; Zhao, J; Zhao, P | 1 |
| Eto, M; Imada, K; Inokuchi, J; Kashiwagi, E; Murakami, T; Shiota, M; Takeuchi, A; Tatsugami, K | 1 |
| Eto, M; Inokuchi, J; Kobayashi, T; Namitome, R; Shiota, M; Tatsugami, K | 1 |
| Kretschmer, A; Todenhöfer, T | 1 |
| Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
| Halabi, S; Parelukar, WR; Rydzewska, L; Tierney, JF; Vale, CL | 1 |
| Buonerba, C; Di Lorenzo, G; Fizazi, K; Pagliuca, M | 1 |
| Feng, FY; Fizazi, K; Vicier, C | 1 |
| Attard, G; Casadio, V; Castro, E; Conteduca, V; De Giorgi, U; Farolfi, A; Gonzalez-Billalabeitia, E; González-Del-Alba, A; Gurioli, G; Hernando, S; Jayaram, A; Lolli, C; Marin-Aguilera, M; Maugeri, A; Medina, A; Mellado, B; Morales-Barrera, R; Olmos, D; Puente, J; Rodriguez-Vida, A; Romero-Laorden, N; Salvi, S; Scarpi, E; Schepisi, G; Vidal, MJM; Villa-Guzmán, JC; Wetterskog, D; Wingate, A | 1 |
| James, ND | 1 |
| Aguiar, PN; Barreto, CMN; Giglio, AD; Gutierres, BS; Lopes, GL; Simko, S; Tan, PS | 1 |
| Alsinnawi, M; Balk, S; Bianchi-Frias, D; Burns, J; Cho, E; Montgomery, RB; Mostaghel, EA; Nelson, PS; Porter, C; Slee, AE; Sowalsky, A; Taplin, ME; True, L; Ye, H; Zhang, A; Zhang, X | 1 |
| Barata, PC; Sartor, AO | 1 |
| Anderson, AR; Brown, JS; Dinh, MN; Gatenby, RA; West, JB; Zhang, J | 1 |
| Aprikian, AG; Bladou, F; Cury, F; Dragomir, A; Hu, J; Kassouf, W; Lahcene, H; Perreault, S; Vanhuyse, M | 1 |
| Battaglia, A; De Meerleer, G; Devos, G; Everaerts, W; Joniau, S; Moris, L; Tosco, L; Van den Broeck, T | 1 |
| Hammerer, P; Manka, L | 1 |
| Cotogno, P; Feibus, A; Ledet, E; Lewis, B; Sartor, O; Schiff, JP; Steinwald, P | 1 |
| Chouahnia, K; Culine, S; Fossey-Diaz, V; Guetz, GD; Landre, T; Taleb, C | 1 |
| Chapin, BF; Ranasinghe, WKB; Reichard, CA | 1 |
| Armstrong, CM; Cai, D; Chen, J; Chen, N; Dai, J; Guo, W; Liu, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Yin, X; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhao, P; Zhu, S; Zhu, X | 1 |
| Beck, JR; Correa, AF; Geynisman, DM; Handorf, EA; Ramamurthy, C | 1 |
| Autorino, R; Castellan, P; Cindolo, L; Di Nicola, M; Marchioni, M; Novara, G; Paul, AK; Primiceri, G; Schips, L; Veccia, A | 1 |
| Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
| Azuma, H; Fujiwara, Y; Hirano, H; Ibuki, N; Ichihashi, A; Inamoto, T; Komura, K; Matsunaga, T; Minami, K; Nishimoto, Y; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanaka, T; Tanda, N; Taniguchi, K; Tsujino, T; Tsutsumi, T; Uchimoto, T; Uehara, H; Yoshikawa, Y | 1 |
| Gotoh, M; Hattori, K; Hattori, R; Ishikawa, T; Kato, M; Kawanishi, H; Naito, Y; Sano, T; Tochigi, K; Tsuzuki, T; Yamamoto, A; Yuba, T | 1 |
| Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
| Assenholt, J; Hansen, TF; Madsen, JS; Osther, PJS; Zedan, AH | 1 |
| Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E | 1 |
| Casadei, C; Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D; Stellato, M; Tonini, G | 1 |
| Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M | 1 |
| Cookson, MS; Parker, DC | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovský, J; Miller, K; Saad, F; Sartor, O; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Csizmarik, A; Fazekas, T; Grünwald, V; Hadaschik, B; Hüttl, A; Jurányi, Z; Kocsis, Z; Kramer, G; Maj-Hes, A; Nyirády, P; Püllen, L; Sevcenco, S; Shariat, SF; Szarvas, T | 1 |
| Csizmarik, A; Keresztes, D; Küronya, Z; Nagy, N; Nyirády, P; Riesz, P; Szarvas, T; Váradi, M | 1 |
| Baston, C; Gingu, C; Guler-Margaritis, SS; Preda, A; Sinescu, I | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
| Egawa, S; Fukuokaya, W; Kimura, S; Kimura, T; Koike, Y; Miki, K; Sasaki, H; Tashiro, K; Tsuzuki, S; Urabe, F | 1 |
| Chang, EM; Deville, C; Feng, FY; Kishan, AU; Koontz, BF; Nickols, NG; Ost, P; Parikh, NR; Phillips, R; Raldow, AC; Reiter, RE; Rettig, MB; Spratt, DE; Steinberg, ML; Tran, PT; Vapiwala, N | 1 |
| Hamilou, Z | 1 |
| Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Griebling, TL | 1 |
| Csizmarik, A; Fazekas, T; Grünwald, V; Hadaschik, B; Hüttl, A; Kramer, G; Maj-Hes, A; Nyirády, P; Sevcenco, S; Shariat, SF; Szarvas, T; Tschirdewahn, S; Váradi, M | 1 |
| Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shigehara, K; Shimada, T; Yaegashi, H | 1 |
| Fontana, F; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM; Raimondi, M | 1 |
| Li, Q; Xie, D; Zhang, PF | 1 |
| Avcı, S; Kırca, M; Ozpolat, B; Soylu, H; Ustunel, I | 1 |
| Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
| Eto, M; Inokuchi, J; Kashiwagi, E; Kobayashi, S; Koura, M; Matsumoto, T; Monji, K; Shiga, KI; Shiota, M; Takeuchi, A; Ueda, S; Yokomizo, A | 1 |
| Arranz, JA; Castro, E; Climent, MA; Gallardo, E; González Del Alba, A; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Méndez-Vidal, MJ; Vazquez, S | 1 |
| Ebinç, S; Isikdogan, A; Kaplan, MA; Karaağaç, M; Kaya, AO; Koca, S; Kut, E; Menekşe, S; Oruç, Z; Özyurt, N; Sakin, A; Sever, ÖN; Tatlı, AM; Turhal, NS; Yasin, İ; Zeynelgil, E | 1 |
| Aben, KKH; Bergman, AM; Coenen, JLLM; de Wit, R; Gerritsen, WR; Kuppen, MCP; Mehra, N; Somford, DM; Uyl-de Groot, CA; van den Bergh, ACM; van den Eertwegh, AJM; van Moorselaar, RJA; van Oort, IM; Westgeest, HM | 1 |
| Izard, JP; Robinson, AG; Vera-Badillo, FE | 1 |
| Bilen, MA; Brown, JT; Carthon, B; Caulfield, S; Kucuk, O; Lafollette, J; Liu, Y; Moore, M; Nazha, B; Russler, G; Smith, KER; Wan, L; Yantorni, L | 1 |
| Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Chen, J; Chen, N; Chen, X; Dai, J; He, B; Liang, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Tao, R; Wang, Z; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhu, S; Zhu, X | 1 |
| Attard, G; Birtle, A; Brawley, CD; Chowdhury, S; Clarke, NW; Cook, AD; Dearnaley, DP; Fackrell, D; Gale, J; Gilbert, DC; Gillessen, S; Gray, E; Hoskin, P; James, ND; Jones, RJ; Langley, RE; Macnair, A; Malik, ZI; Matheson, D; McPhail, N; Millman, R; Morgans, AK; Murphy, L; O'Sullivan, JM; Parker, CC; Parmar, MKB; Perna, C; Protheroe, A; Pugh, C; Rudman, S; Rush, HL; Russell, JM; Sydes, MR; Tanguay, JS; Tolan, S; Vengalil, S; Wagstaff, J | 1 |
| Blanchet, P; Brureau, L; Gourtaud, G; Roux, V; Sadreux, Y; Senechal, C; Vestris, PG | 1 |
| Armstrong, AJ; Dzimitrowicz, HE | 1 |
| Chiba, S; Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Horikawa, Y; Ishida, T; Kashima, S; Kimura, T; Koizumi, A; Kumazawa, T; Maita, S; Narita, S; Nomura, K; Ohyama, C; Okane, K; Sato, H; Shimoda, J; Suzuki, T; Takayama, K; Yamamoto, R; Yanagisawa, T | 1 |
| Abadie-Lacourtoisie, S; Berdah, JF; Berthold, D; Bossi, A; Calabro, F; Carles, J; Chand-Fouche, ME; El Kouri, C; Escande, A; Fizazi, K; Fléchon, A; Foulon, S; Freixa, SV; Gravis, G; Hasbini, A; Jamaluddin, M; Kacso, G; Laguerre, B; Latorzeff, I; Magne, N; Martin, E; McDermott, R; Mourey, L; Priou, F; Rieger, I; Ronchin, P; Rosello, A; Roubaud, G; Schlurmann, F; Silva, M; Supiot, S; Thiery-Vuillemin, A; Tombal, B | 1 |
| Calais, G; Cancel, M; Florence, AM; Fromont, G; Laurent, E; Linassier, C; Narciso, B; Pobel, C | 1 |
| Fujimoto, N; Fukuda, A; Harada, K; Hiroshige, T; Igawa, T; Minato, A; Mizushima, Y; Nagata, Y; Obara, W; Tomisaki, I | 1 |
| Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P | 1 |
| Habuchi, T; Hamaya, T; Hashimoto, Y; Hata, K; Hatakeyama, S; Kimura, T; Narita, S; Ohyama, C; Okamoto, T; Ozaki, K; Tanaka, T; Togashi, K; Yamamoto, H; Yanagisawa, T; Yoneyama, T | 1 |
| Enei, Y; Fukuokaya, W; Habuchi, T; Hara, S; Hata, K; Hatakeyama, S; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Nakazono, M; Narita, S; Ohyama, C; Otsuka, T; Sano, T; Shariat, SF; Yanagisawa, T; Yata, Y | 1 |
| Abida, W; Bambury, RM; Bryce, AH; Chowdhury, S; Daugaard, G; Despain, D; Emmenegger, U; Fizazi, K; Gingerich, JR; Heidenreich, A; Heyes, CA; Krieger, L; Lindberg, H; Loehr, A; McDermott, R; Morris, D; Nolè, F; Ostler, P; Pintus, E; Piulats, JM; Reaume, MN; Redfern, C; Ryan, CJ; Sáez, MI; Sautois, B; Sridhar, SS; Staffurth, J; Watkins, SP | 1 |
| Deris, A; Sohrabi-Haghighat, M | 1 |
| Cai, D; Chen, J; Chen, N; Chen, Y; Dai, J; Hu, X; Liang, J; Liu, H; Liu, Z; Ni, Y; Nie, L; Pan, X; Shen, P; Sun, G; Wang, M; Wang, Z; Xu, N; Yin, W; Yin, X; Zeng, H; Zeng, Y; Zhang, X; Zhang, Y; Zhao, F; Zhao, J; Zheng, L; Zhu, S; Zhu, X | 1 |
52 review(s) available for docetaxel anhydrous and abiraterone
| Article | Year |
|---|---|
New options for the management of castration-resistant prostate cancer: a case perspective.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Immunotherapy; Male; Prostatectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2011 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
Current clinical trials in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
New treatment options for castrate-resistant prostate cancer: a urology perspective.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts | 2011 |
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Survival Rate; Taxoids; Tissue Extracts | 2012 |
Castration-resistant prostate cancer: systemic therapy in 2012.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Thiohydantoins | 2012 |
Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
Topics: Androgen Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; Cathepsin K; Dendritic Cells; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Radiopharmaceuticals; RANK Ligand; Receptors, Endothelin; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; src-Family Kinases; Taxoids; Tissue Extracts | 2014 |
Management of advanced prostate cancer in senior adults: the new landscape.
Topics: Aged; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Castration; Clinical Trials as Topic; Disease Management; Docetaxel; Drug Resistance, Neoplasm; Humans; Life Expectancy; Male; Prostate; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure | 2012 |
[The treatment of castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cancer Vaccines; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Oligonucleotides, Antisense; Orchiectomy; Prostatic Neoplasms; Protein-Tyrosine Kinases; RANK Ligand; Receptors, Vascular Endothelial Growth Factor; Taxoids; Tissue Extracts; Treatment Failure | 2012 |
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts | 2013 |
[Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Docetaxel; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2013 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2013 |
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Prostate cancer in 2014: The year chemotherapy finally gets some respect!
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Corticosteroids in the management of prostate cancer: a critical review.
Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2015 |
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
Advances in the management of castration resistant prostate cancer.
Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Management; Docetaxel; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.
Topics: Androstenes; Benzamides; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2017 |
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
Topics: Androgen Antagonists; Androstenes; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Progression-Free Survival; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2018 |
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2018 |
Current approaches to incorporation of radium-223 in clinical practice.
Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Treatment Outcome | 2018 |
Treatment of hormone-naïve metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Asia, Eastern; Asia, Southeastern; Combined Modality Therapy; Consensus; Developing Countries; Docetaxel; Humans; Lymph Node Excision; Male; Neoplasm Metastasis; Oceania; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Risk Factors | 2019 |
Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2018 |
[DNA damage repair: An emerging strategy in metastatic prostate cancer].
Topics: Androstenes; Antineoplastic Agents; Benzamides; DNA Damage; DNA Repair; Docetaxel; Genomic Instability; Humans; Male; Nitriles; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.
Topics: Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms, Castration-Resistant | 2018 |
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Retrospective Studies; Taxoids; Thiohydantoins; Tissue Extracts | 2019 |
Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
Topics: Androstenes; Docetaxel; Humans; Male; Medical Oncology; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic | 2019 |
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or….
Topics: Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant | 2019 |
Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Topics: Androgen Antagonists; Androstenes; Combined Modality Therapy; Docetaxel; Humans; Lymph Node Excision; Male; Metastasectomy; Neoplasm Metastasis; Prostatic Neoplasms; Standard of Care | 2019 |
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2019 |
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2019 |
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Tumor Microenvironment | 2020 |
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Grading; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2020 |
Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Hormones; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2020 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
The evolving options in metastatic castration-sensitive prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions.
Topics: Androstenes; Animals; Benzamides; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, LHRH; Signal Transduction | 2020 |
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
23 trial(s) available for docetaxel anhydrous and abiraterone
| Article | Year |
|---|---|
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Glucocorticoids; Humans; Hyperaldosteronism; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids | 2010 |
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone | 2012 |
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Survival Rate; Taxoids; Time Factors | 2014 |
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids | 2015 |
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Topics: Aged; Androgens; Androstenes; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Incidence; Male; Orchiectomy; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Survival Rate; Taiwan; Taxoids; Treatment Failure | 2014 |
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Dietary Fats; Docetaxel; Double-Blind Method; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Young Adult | 2014 |
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2015 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2017 |
'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial.
Topics: Androstenes; Antineoplastic Agents; Data Interpretation, Statistical; Docetaxel; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2017 |
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
Topics: Adult; Aged; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
Topics: Aged; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Blood Platelets; Disease-Free Survival; Docetaxel; Glutamate Carboxypeptidase II; Humans; Kallikreins; Male; Middle Aged; Neuropeptide Y; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Canada; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Service, Hospital; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Multivariate Analysis; Nitriles; Ontario; Phenylthiohydantoin; Population Surveillance; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Italy; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2018 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Radiotherapy; Taxoids; Treatment Outcome; Tubulin Modulators | 2019 |
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Quality of Life | 2022 |
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Female; Humans; Hypertension; Male; Prednisone; Prostatic Neoplasms | 2022 |
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Pain; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone | 2022 |
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Genes, BRCA1; Genes, BRCA2; Humans; Indoles; Male; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2023 |
114 other study(ies) available for docetaxel anhydrous and abiraterone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
New treatment options for patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
Novel and bone-targeted agents for CRPC.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment | 2012 |
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Cost-Benefit Analysis; Docetaxel; Drug Costs; Evidence-Based Medicine; Humans; Male; Practice Guidelines as Topic; Prednisolone; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Terminal Care; Time Factors; Treatment Outcome; United Kingdom | 2012 |
Abiraterone and its place in the treatment of metastatic CRPC.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2013 |
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure | 2014 |
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Disease Progression; Docetaxel; Estrogens, Non-Steroidal; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome | 2013 |
The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for
Topics: Adult; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Approval; European Union; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Benzamides; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Towards random sequencing or precision medicine in castration-resistant prostate cancer?
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
Topics: Active Transport, Cell Nucleus; Androstenes; Androstenols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Green Fluorescent Proteins; Humans; Male; Microscopy, Confocal; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Time-Lapse Imaging | 2013 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2014 |
Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure | 2014 |
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2014 |
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Lung Neoplasms; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Signal Transduction; Taxoids; Time Factors; Treatment Outcome | 2015 |
Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2015 |
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Compassionate Use Trials; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Europe; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Canada; Cytochrome P-450 Enzyme Inhibitors; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2015 |
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Endpoint Determination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure | 2015 |
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2015 |
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Academic Medical Centers; Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Baltimore; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Patient Selection; Phenotype; Phenylthiohydantoin; Predictive Value of Tests; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Risk Factors; RNA, Messenger; Taxoids; Time Factors; Treatment Outcome | 2015 |
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
[Chemotherapy of prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Therapy; Evidence-Based Medicine; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Drug Monitoring; Drug Resistance, Neoplasm; Drug Substitution; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Netherlands; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Viscera | 2015 |
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
Topics: Androstenes; Androstenols; Benzamides; Bridged-Ring Compounds; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Topics: Adenocarcinoma; Androgens; Androstenes; Animals; Antineoplastic Agents, Phytogenic; Benzamides; Biological Transport; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterografts; Humans; Male; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Organic Anion Transporters, Sodium-Independent; Phenylthiohydantoin; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2016 |
Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
Topics: Abiraterone Acetate; Aged, 80 and over; Androstenes; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Safety-Based Drug Withdrawals; Taxoids; Time Factors; Treatment Outcome | 2017 |
Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Topics: Aged; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Japan; Male; Patient Preference; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2016 |
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Topics: Aged; Androstenes; Benzamides; Docetaxel; Drug Costs; Health Care Costs; Humans; Male; Medicare; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; United States | 2017 |
First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Topics: Age Factors; Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Bone and Bones; Docetaxel; Humans; Male; Medical Audit; Medical Oncology; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Oncology; Radionuclide Imaging; Regression Analysis; Surveys and Questionnaires; Taxoids; Tumor Burden; Urology | 2017 |
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators | 2018 |
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2017 |
Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Chlorine; Choline; Docetaxel; Gene Dosage; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction | 2017 |
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Testosterone | 2018 |
Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2018 |
Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Propensity Score; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Glucocorticoids; Humans; Male; Prostatic Neoplasms; Survival Analysis; United States | 2018 |
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Survival Rate; Taxoids | 2018 |
The case for 'successfully' treating hormone naïve metastatic prostate cancer.
Topics: Androstenes; Docetaxel; Humans; Male; Prostatic Neoplasms | 2018 |
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2018 |
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncolo
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells.
Topics: A549 Cells; Androstenes; Delayed-Action Preparations; Docetaxel; Drug Carriers; Humans; Nanoparticles; Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer | 2019 |
Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Testosterone | 2019 |
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biopsy, Large-Core Needle; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Orchiectomy; Prognosis; Progression-Free Survival; Prostate; Prostatic Neoplasms; Retrospective Studies; Risk Assessment | 2019 |
Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2019 |
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spain; Time Factors | 2019 |
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
Topics: Androstenes; Cost of Illness; Docetaxel; Humans; Male; Molecular Biology; Neoplasm Metastasis; Phenotype; Positron-Emission Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Tubulin Modulators; Whole Body Imaging | 2019 |
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cost-Benefit Analysis; Docetaxel; Humans; Male; Placebos; Progression-Free Survival; Prostatic Neoplasms; Quality-Adjusted Life Years; Reference Values; Reproducibility of Results; Time Factors; Treatment Outcome | 2019 |
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
Topics: Adult; Aged; Androgen Antagonists; Androstenes; Dehydroepiandrosterone Sulfate; Disease Progression; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Grading; Organic Anion Transporters; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Treatment Outcome | 2019 |
Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Models, Theoretical; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Simulation Training; Survival Rate; Treatment Outcome | 2019 |
Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Clinical Decision-Making; Cohort Studies; Docetaxel; Humans; Male; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2020 |
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Docetaxel; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Time Factors | 2019 |
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Standard of Care; Tumor Burden | 2019 |
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Image-Guided Biopsy; Immunohistochemistry; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
Topics: Androstenes; Cost-Benefit Analysis; Docetaxel; Humans; Male; Prostatic Neoplasms | 2019 |
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Network Meta-Analysis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Thiohydantoins | 2020 |
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.
Topics: Aged; Albumins; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; C-Reactive Protein; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2019 |
Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
Topics: Administration, Oral; Aged; Androstenes; Antineoplastic Agents; Benzamides; Biopsy; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Propensity Score; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome | 2020 |
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids | 2020 |
Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Circulating MicroRNA; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2020 |
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2020 |
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Tissue Extracts | 2020 |
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Androstenes; Antineoplastic Agents; Benzamides; Chromogranin A; Docetaxel; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Phosphopyruvate Hydratase; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Proton Pump Inhibitors; Survival Rate | 2021 |
Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Benzamides; Biomarkers, Tumor; Docetaxel; Erythrocytes; Humans; Male; Mean Platelet Volume; Nitriles; Phenylthiohydantoin; Platelet Count; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome | 2020 |
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Confidence Intervals; Cost-Benefit Analysis; Docetaxel; Humans; Male; Markov Chains; Monte Carlo Method; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Radiosurgery; Salvage Therapy; Time Factors | 2020 |
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2020 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2020 |
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Matrix Metalloproteinase 7; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2021 |
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Risk Factors; Signal Transduction; Taxoids | 2021 |
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2021 |
Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.
Topics: Androgen Antagonists; Androstenes; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Male; Neoplasm Metastasis; Prostatic Neoplasms; Receptor, Notch1; RNA, Messenger; Transcription Factor HES-1 | 2021 |
Prognostic impact of prior local therapy in castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis | 2021 |
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Docetaxel; Genes, BRCA1; Genes, BRCA2; Genetic Testing; Humans; Male; Medical Oncology; Nitriles; Orchiectomy; Phenylthiohydantoin; Phthalazines; Piperazines; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic; Societies, Medical; Spain; Thiohydantoins | 2021 |
Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2021 |
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
Topics: Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Patient Selection; Pharmaceutical Preparations; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostate; Prostatic Neoplasms, Castration-Resistant | 2021 |
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Topics: Androstenes; Black or African American; Docetaxel; Georgia; Health Status Disparities; Hormones; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 2021 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2021 |
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Progression-Free Survival; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Topics: Androstenes; Antineoplastic Agents; Benzamides; Black People; Docetaxel; Guadeloupe; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
Topics: Androstenes; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Quality of Life | 2022 |
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Propensity Score; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2022 |
Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Benzamides; Brain Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
Topics: Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2022 |
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Female; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |